Search results for " enzyme"

showing 10 items of 791 documents

The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prosta…

2017

Two new drugs, the CYP17 inhibitor abiraterone acetate and the androgen receptor (AR) antagonist enzalutamide, have recently shown to prolong OS prior chemotherapy or in docetaxel treated mCRPC patients, using steroidal therapy or placebo as control group. Updated analyses underlined the role of these new agents on two prostate-specific endpoints as radiographic progression-free survival (rPFS) and time to first skeletal-related event (tSRE). On the basis of these reports, we made an indirect comparison between abiraterone and enzalutamide. We obtained a clinically but not significant difference favouring enzalutamide over abiraterone in terms of rPFS (HR 0.48, 95% CI 0.22–1.02). No signi…

Malemedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentUrologyAbiraterone AcetateBone NeoplasmsAbiraterone; Enzalutamide; mCRPC; rPFS; tSRE; Hematology; Oncology; Geriatrics and GerontologyPlaceboDisease-Free Survivallaw.invention03 medical and health scienceschemistry.chemical_compoundProstate cancer0302 clinical medicineRandomized controlled triallawNitrilesPhenylthiohydantoinEnzalutamideAndrogen Receptor AntagonistsMedicineEnzalutamideCytochrome P-450 Enzyme InhibitorsHumans030212 general & internal medicineProgression-free survivalAbirateronetSRERandomized Controlled Trials as TopicChemotherapybusiness.industryAbiraterone acetateHematologymCRPCmedicine.diseaseProstatic Neoplasms Castration-ResistantTreatment OutcomechemistryDocetaxelrPFSOncology030220 oncology & carcinogenesisBenzamidesDisease ProgressionGeriatrics and Gerontologybusinessmedicine.drugCritical reviews in oncology/hematology
researchProduct

Role of thyroid state on induction by ciprofibrate of laurate hydroxylase and peroxisomal enzymes in rat liver microsomes.

1993

The effects of hypothyroidism and hyperthyroidism upon liver microsomal omega-laurate hydroxylase activity (cytochrome P450 IV A1-dependent), peroxisome proliferation marker enzyme activities and acyl CoA oxidase (AOX) expression induced by ciprofibrate (2 mg/kg/day during 8 days) were studied in the male Wistar rat so as to clarify firstly the possible involvement of thyroid hormones in the modification of peroxisomal ciprofibrate-induced enzyme activities in relation to hepatic microsomal cytochrome P450 IV A1 induction, and secondly the possible direct effect of thyroid hormones on the gene expression of specific peroxisomal enzymes. No significant change was found in the ciprofibrate-in…

Malemedicine.medical_specialtyThyroid HormonesPeroxisome ProliferationGlucuronatesGlycerolphosphate DehydrogenaseBiochemistryMicrobodiesMixed Function OxygenasesClofibric AcidCytochrome P-450 Enzyme SystemInternal medicinemedicineAnimalsEnzyme inducerRats WistarPharmacologyTriiodothyroninebiologyBody WeightFibric AcidsCytochrome P450Organ SizePeroxisomeEnoyl-CoA hydrataseRatsEndocrinologyGene Expression RegulationEnzyme InductionProtein Biosynthesisbiology.proteinMicrosomes LiverCiprofibrateCytochrome P-450 CYP4Amedicine.drugHormoneBiochemical pharmacology
researchProduct

Effects of clinical and laboratory variables at admission and of in-hospital treatment with cardiovascular drugs on short term prognosis of ischemic …

2011

Abstract Introduction No information exists, to our knowledge, about the possible role of cardiovascular drug administration in the acute phase of ischemic stroke and possible effects on stroke outcome. The aim of our study was to evaluate the relationship between in-hospital treatment with cardiovascular drugs in patients with acute ischemic stroke and some outcome indicators. Methods and Results 1096 subjects enrolled in the GIFA study, who had a main discharge diagnosis of ischemic stroke represent the final sample. Drugs considered for the analysis were the following: ACE-inhibitors (ACEI), angiotensin II receptor blockers (ARBs), statins, calcium-channel-blockers (CCBs), antiplatelet (…

Malemedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismHypercholesterolemiaMedicine (miscellaneous)Angiotensin II Receptor BlockersCharlson indexAngiotensin-Converting Enzyme InhibitorsComorbidityBrain IschemiaInternal medicineActivities of Daily LivingmedicineHumansIn patientcardiovascular diseasesStrokeGeriatric AssessmentAgedRetrospective StudiesNutrition and Dieteticsbusiness.industryCardiovascular AgentsHeparinmedicine.diseaseCalcium Channel BlockersPrognosisStrokeHospital treatmentItalyIschemic strokeHypertensionPhysical therapyFunctional statusFemaleCardiology and Cardiovascular MedicinebusinessCognition DisordersPlatelet Aggregation Inhibitorsmedicine.drugNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Differential inhibition of biphenyl hydroxylation in perfused rat liver

1978

A differential inhibition of biphenyl hydroxylation by alpha-naphthoflavone and metyrapone was observed in isolated perfused rat liver. alpha-Naphthoflavone inhibited 2- and 4-hydroxylation in livers from beta-naphthoflavone-pretreated animals but had no effect on both reactions in livers from phenobarbital-pretreated animals. Metyrapone inhibited 2- and 4-hydroxylation in phenobarbital-stimulated livers, but only insignificant inhibition of 2-hydroxylation and a slight enhancement of 4-hydroxylation by metyrapone was observed in beta-naphthoflavone-stimulated livers. Conjugation of 2-hydroxybiphenyl and 4-hydroxybiphenyl by isolated perfused livers was also studied. 4-Hydroxybiphenyl prefe…

Malemedicine.medical_specialtyTime FactorsPharmacology toxicologyHydroxylationDifferential inhibitionHydroxylationchemistry.chemical_compoundCytochrome P-450 Enzyme SystemBiphenyl metabolismInternal medicinemedicineAnimalsFlavonoidsPharmacologyBiphenylMetyraponeBiphenyl CompoundsGeneral MedicineMetyraponeRatsEndocrinologyLiverchemistryDepression ChemicalPhenobarbitalRat livermedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Effect of endurance training on the capacity of red and white skeletal muscle of mouse to oxidize carboxyl-14C-labelled palmitate.

1977

Three groups of mice were trained for 1, 4 and 5 months according to different running programs on a motor driven treadmill and the fatty acid oxidation capacity (FAO) and the activities of some enzymes of energy metabolism (cytochrome c oxidase, malate dehydrogenase, triosephosphate dehydrogenase, and lactate dehydrogenase) were determined from m. quadriceps femoris (MQF). Endurance training increased the FAO [5-month training 4 days/week, 30 min/day 22% (p less than 0.05); 1-month training, 7 days/week, 150 min/day 37% (p less than 0.001); 4-month training, 5 days/week, 60 min/day 24% (p less than 0.05)]. The activities of cytochrome c oxidase and malate dehydrogenase increased approx. 30…

Malemedicine.medical_specialtyTime FactorsPhysiologyPhysical ExertionPalmitatesPalmitic AcidsBiologyMalate dehydrogenaseElectron Transport Complex IVchemistry.chemical_compoundMiceEndurance trainingMalate DehydrogenaseLactate dehydrogenaseInternal medicineOxidative enzymemedicineCytochrome c oxidaseAnimalsCarbon RadioisotopesBeta oxidationchemistry.chemical_classificationL-Lactate DehydrogenaseMusclesSkeletal muscleGlyceraldehyde-3-Phosphate DehydrogenasesEnzymeEndocrinologymedicine.anatomical_structurechemistrybiology.proteinOxidation-ReductionActa physiologica Scandinavica
researchProduct

Comparative changes between pancreas and pancreatic juice digestive enzyme contents during nutritional rehabilitation following severe protein malnut…

1993

The relationship between digestive enzyme activities in the pancreas and pancreatic juice was studied in post-weaning rats fed on a low-protein diet (30 g cereal protein/kg) for 1 month and a refeeding balanced diet (235 g mixed protein/kg) for the following 3 months. A control group was fed on the balanced diet for 4 months. At the end of malnutrition and at various times of refeeding, activities of amylase (EC3.2.1.1), trypsin(EC3.4.21.4), chymotrypsin (EC3.4.21.1), lipase (EC3.1.1.3), phospholipase A2 (EC3.1.1.4) and cholesterolesterase (EC3.1.1.13) in pancreas and pancreatic juice were measured. Recovery of body and pancreas weights was obtained after 3 months of refeeding. Pancreas off…

Malemedicine.medical_specialtyTime FactorsProtein–energy malnutritionDiet therapyMedicine (miscellaneous)Protein-Energy MalnutritionPhospholipases APancreatic JuiceInternal medicinemedicineAnimalsChymotrypsinTrypsinAmylaseRats WistarPancreasNutrition and DieteticsChymotrypsinbiologyLipaseSterol Esterasemedicine.diseaseTrypsinRatsPhospholipases A2Endocrinologymedicine.anatomical_structureAmylasesPancreatic juiceDigestive enzymebiology.proteinRNAPancreasmedicine.drugBritish Journal of Nutrition
researchProduct

Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study

2020

Altres ajuts: Conselleria d'Educació, Investigació, Cultura i Esport GV/2018/116 Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma low-density lipoprotein cholesterol. Beyond lipid control, recent findings suggest a deleterious effect of this protein in the pathogenesis of postmyocardial infarction left ventricle remodelling and heart failure-related complications. The aim of this study was to assess the relationship between circulating PCSK9 and 6 month cardiac magnetic resonance imaging-derived left ventricular ejection fraction (LVEF) after a first ST-segment elevation myocardial infarction (STEMI). We prospectively evaluated 40…

Malemedicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemLeft ventricular ejection fractionCardiac magnetic resonancemedicine.medical_treatmentMyocardial InfarctionInfarctionAngiotensin-Converting Enzyme InhibitorsPilot Projects030204 cardiovascular system & hematologyVentricular Function LeftPCSK9Angiotensin Receptor Antagonists03 medical and health sciences0302 clinical medicineCardiac magnetic resonance imagingOriginal Research ArticlesInternal medicinemedicineST‐segment elevation myocardial infarctionHumansST segmentOriginal Research Article030212 general & internal medicineMyocardial infarctioncardiovascular diseasesAgedKillip classEjection fractionmedicine.diagnostic_testbusiness.industryPercutaneous coronary interventionStroke VolumeMiddle Agedmedicine.diseaseST-segment elevation myocardial infarctionlcsh:RC666-701Heart failureCardiologyST Elevation Myocardial InfarctionProprotein Convertase 9Cardiology and Cardiovascular Medicinebusiness
researchProduct

Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the Ath…

2005

Aims Metalloproteinases are proteolytic enzymes, which decompose the extracellular matrix, influence cardiac remodelling, and are inhibited by tissue inhibitor of metalloproteinases (TIMPs). Little is known about the prognostic impact of the TIMP-1/matrix metalloproteinase complex in patients with future cardiovascular death. Methods and results In 1979 patients with suspected coronary artery disease (CAD), TIMP-1 has been determined at baseline. Among 1945 (98.4%) patients with a mean follow-up period of 2.6±1.2 years, 75 patients died because of cardiovascular causes. Mean concentrations of TIMP-1 were higher among patients who experienced a fatal cardiovascular event than among those who…

Malemedicine.medical_specialtymedicine.drug_classDiseaseCoronary Artery DiseaseCoronary artery diseaseRisk FactorsInternal medicinemedicineNatriuretic peptideHumansTissue Inhibitor of Metalloproteinase-1business.industryHazard ratioConfoundingProteolytic enzymesTissue inhibitor of metalloproteinaseMiddle Agedmedicine.diseasePrognosisEndocrinologyCardiovascular DiseasesCirculatory systemCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesEuropean heart journal
researchProduct

Effectiveness and Tolerability of Fixed-Dose Combination Enalapril plus Nitrendipine in Hypertensive Patients Results of the 3-Month Observational, P…

2009

Background and objective: Monotherapy with any class of antihypertensive drug effectively controls blood pressure (BP) in only about 50% of patients. Consequently, the majority of patients with hypertension require combined therapy with two or more medications. This study aimed to evaluate the effectiveness (systolic BP [SBP]/diastolic BP [DBP] control) and tolerability of the fixed-dose combination enalapril/nitrendipine 10 mg/20 mg administered as a single daily dose in hypertensive patients. Methods: This was a post-authorization, multicentre, prospective, observational study conducted in primary care with a 3-month follow-up. Patients throughout Spain with uncontrolled hypertension (>= …

Malemedicine.medical_specialtymedicine.drug_classSystolic hypertensionFixed-dose combinationPopulationAngiotensin-Converting Enzyme InhibitorsBlood PressureEssential hypertensionEnalaprilInternal medicinemedicineProduct Surveillance PostmarketingHumansPharmacology (medical)EnalaprilProspective StudieseducationAntihypertensive drugAntihypertensive Agentseducation.field_of_studyDose-Response Relationship DrugPrimary Health Carebusiness.industryNitrendipineGeneral MedicineMiddle Agedmedicine.diseaseCalcium Channel BlockersDrug CombinationsBlood pressureTolerabilityAnesthesiaHypertensionFemalebusinessmedicine.drug
researchProduct

Antihypertensive effects of lactoferrin hydrolyzates: Inhibition of angiotensin- and endothelin-converting enzymes

2013

The potential of bovine lactoferrin (LF) as a source of antihypertensive peptides acting on the renin-angiotensin system (RAS) and the endothelin (ET) system as dual vasopeptidase inhibitors has been examined. For this purpose enzymatic LF hydrolyzates (LFHs) were generated by trypsin and proteinase K digestions. Permeate fractions with molecular masses lower than 3 kDa (LFH <3 kDa) were orally administered to spontaneously hypertensive rats (SHRs). Although both LFHs <3 kDa showed in vitro angiotensin I-converting enzyme (ACE)-inhibitory activity, only proteinase K LFH <3 kDa exerted an in vivo antihypertensive effect. The proteinase K LFH <3 kDa and a previously characterized pepsin LFH <…

Malemedicine.medical_treatmentLactoferrin hydrolyzatesMolecular Sequence DataPeptideAngiotensin-Converting Enzyme InhibitorsBlood PressureIn Vitro TechniquesPeptidyl-Dipeptidase AECE-dependent vasoconstrictionAnalytical ChemistryIn vivoRats Inbred SHRmedicineVasopeptidase InhibitorsAnimalsAmino Acid SequenceAntihypertensive Agentschemistry.chemical_classificationProteasebiologyLactoferrinEndothelinsHydrolysisGeneral MedicineVasopeptidase inhibitorsRenin–angiotensin systemProteinase KTrypsinEndothelin systemRatsLactoferrinEnzymeCarotid ArteriesBiochemistrychemistryVasoconstrictionHypertensionbiology.proteinCattleRabbitsFood Sciencemedicine.drugACE-dependent vasoconstriction
researchProduct